Loading stock data…
NRSN
$0.90+0.08 (+9.21%)
Market ClosedLast close May 1
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NeuroSense Therapeutics Ltd. in the Healthcare sector is trading at $0.90. The stock is currently near its 52-week low of $0.63, remaining 14.6% below its 200-day moving average. Technical signals show overbought RSI of 83 and bullish MACD crossover, explaining why NRSN maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 83) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.90
Potential Upside
5%
Whystock Fair Value$0.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is Prim...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
713.14%
Volume
Today's trading volume
185,094
Recent News
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and th
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Last Wednesday, NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) said it scaled up its production of PrimeC to a commercial scale. PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation with a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. NeuroSense said it bolstered its supply chain by implementing comprehensive Chemistry, Manufacturing, and Controls (CMC) enhan